분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2017-12-22 19:18:04 , Hit : 509
 FDA Approves First Gene Therapy for Inherited Disease

https://www.genengnews.com/gen-news-highlights/fda-approves-first-gene-therapy-for-inherited-disease/81255291/?utm_medium=newsletter&utm_source=gen+daily+news+highlights&utm_content=01&utm_campaign=gen+daily+news+highlights_20171220

December 20, 2017


FDA approved Spark Therapeutics’ gene therapy Luxturna™   (voretigene neparvovec-rzyl) for treating children and adults with the rare inherited blindness disorder biallelic RPE65 mutation-associated retinal dystrophy. Approval of the one-time adeno-associated virus vector (AAV)-delivered gene therapy, which FDA Commissioner Scott Gottlieb, M.D., described in a statement as “a milestone that reinforces the potential of this breakthrough approach in treating a wide-range of challenging disease,” marks the first gene therapy approval for a genetic disease. Spark has not confirmed the cost of treatment, although some commentators are anticipating a $1 million per patient price tag. Luxturna is currently under review by the European Medicines Agency.

FDA clearance of Luxturna marks the third approval by the agency for a gene therapy, but the first for an AAV-based treatment. In August this year, the U.S. regulator cleared Novartis’ cell-based chimeric antigen receptor T-cell (CAR-T) gene therapy Kymriah™  (tisagenlecleucel) for treating refractory or relapsed B-cell acute lymphoblastic leukemia. In October, Kite Pharma’s CAR-T therapy Yescarta™ (axicabtagene ciloleucel)  was given the FDA nod for treating refractory or relapsed diffuse large B-cell lymphoma.

Administered as a subretinal injection, Luxturna uses an AAV vector to deliver a normal copy of the RPE65 gene to viable retinal cells in patients with confirmed disease. The gene therapy has been tested in two open-label Phase I studies and one open-label, controlled Phase III study, involving 41 participants aged four to 44 years at the time of treatment.

Luxturna will be administered to patients with genetically confirmed disease, by specially trained surgeons at selected centers in the U.S. Spark anticipates that the gene therapy will be available during the first quarter of 2018. The firm will manufacture Luxturna at its facility in West Philadelphia, which it says is the first manufacturing facility in the U.S. licensed for a gene therapy to treat an inherited disease.

“During the more than 12 years of innovative research with dedicated collaborators near and far, I’ve witnessed the dramatic improvement in vision in many patients who would have otherwise lost their sight,” commented Jean Bennett, M.D. Ph.D., the F.M. Kirby Professor of Ophthalmology in the Perelman School of Medicine at the University of Pennsylvania and Penn’s Scheie Eye Institute. “I believe that the success of the Luxturna clinical development program will pave the way for the development of other gene therapies that may help the millions of patients with genetic diseases who currently have limited or no treatment options.”

“This approval is a watershed milestone,” added Benjamin Yerxa, Ph.D., CEO at the Foundation Fighting Blindness (FFB), a nonprofit organization focused on research for preventing and treating blindness caused by inherited retinal diseases. “For people with an inherited retinal disease and for other patient communities, this decision may create important momentum for investigational gene therapies."

  








1227   암 면역요법, 일부 환자에게만 효과 있는 이유  이성욱 2018/01/12 587
1226   [바이오토픽] CRISPR 기반 유전자치료를 방해하는 면역계  이성욱 2018/01/10 589
1225   [미국] 2017년, 유전자가위 기술을 통한 네 가지 사건들  이성욱 2018/01/10 530
1224   Using Oncolytic Viruses to Boost Response to Immune Checkpoint Inhibitors  이성욱 2018/01/05 835
1223   Alcohol Boosts Cancer Risk by Damaging Stem Cell DNA  이성욱 2018/01/05 508
1222   [바이오토픽] Science, 2017년 과학연구 총결산  이성욱 2017/12/27 1005
  FDA Approves First Gene Therapy for Inherited Disease  이성욱 2017/12/22 509
1220   Spark Therapeutics shares rise on FDA approval of new gene therapy for blindness  이성욱 2017/12/20 368
1219   작년 바이오산업 규모 8조8775억원, 투자 13.9% 늘어  이성욱 2017/12/13 489
1218   CRISPR/Cas9 Edits Epigenome with Therapeutic Efficiency  이성욱 2017/12/09 483
1217   [바이오토픽] 체크포인트 저해제의 부작용: 자가면역질환 초래  이성욱 2017/11/16 685
1216   DNA Repair Mechanism Aids Cancer by Mending Chemo Damage  이성욱 2017/11/10 566
1215   FDA Approves Gilead CAR-T Therapy Yescarta, Plans Regenerative Medicine Policy 'Soon'  이성욱 2017/10/20 607
1214   Advisors to FDA Recommend Approval of Gene Therapy for Blindness  이성욱 2017/10/14 663
1213   CRISPR System Targets RNA in Mammalian Cells  이성욱 2017/10/06 638
1212   Nonviral CRISPR Delivery a Success  이성욱 2017/10/03 554
1211   Giants of Circadian Biology Win Nobel Prize  이성욱 2017/10/03 497
1210   To Speed CRISPR/Cas9’s Search and Snip, Try Extra Cas9 and gRNA  이성욱 2017/09/30 1988
1209   Technique Adapted from CRISPR-Cas9 Corrects Mutation in Human Embryos  이성욱 2017/09/29 502
1208   Mutations Making CRISPR Hyper-Accurate Discovered  이성욱 2017/09/22 850

[1][2] 3 [4][5][6][7][8][9][10]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN